Among 89,000 patients with anemia and CKD (96.7% male, median age 77.5), 7.1% initiated erythropoietin stimulating agents within a year of diagnosis of anemia, while 30.8% initiated iron therapy and 16.5% used blood transfusions in the same time span. The gene discussed is EPO; the disease is chronic kidney disease.